Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$8.92 USD
-0.01 (-0.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.94 +0.02 (0.22%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Centessa Pharmaceuticals PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 7 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 178 | 212 | 375 | 10 | 0 |
Income After Depreciation & Amortization | -171 | -212 | -375 | -10 | 0 |
Non-Operating Income | 5 | 2 | -6 | 0 | NA |
Interest Expense | 10 | 7 | 1 | 0 | NA |
Pretax Income | -176 | -217 | -382 | -11 | NA |
Income Taxes | -25 | -1 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -151 | -216 | -382 | -11 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -151 | -216 | -382 | -11 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -170 | -212 | -375 | -10 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -171 | -212 | -375 | -10 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 96.18 | 93.40 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.57 | -2.31 | NA | NA | NA |
Diluted Net EPS (GAAP) | -1.57 | -2.31 | -5.08 | NA | NA |
Fiscal Year end for Centessa Pharmaceuticals PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 6.85 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 6.85 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 42.04 | 40.21 | 47.02 | 48.88 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -35.19 | -40.21 | -47.02 | -48.88 |
Non-Operating Income | NA | 2.06 | 1.28 | 0.53 | 1.19 |
Interest Expense | NA | 2.57 | 2.54 | 2.45 | 2.35 |
Pretax Income | NA | -35.69 | -41.47 | -48.94 | -50.04 |
Income Taxes | NA | 1.14 | -2.83 | -24.05 | 0.68 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -36.84 | -38.65 | -24.89 | -50.71 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -36.84 | -38.65 | -24.89 | -50.71 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 97.92 | 96.65 | 95.16 | 94.94 |
Diluted EPS Before Non-Recurring Items | NA | -0.38 | -0.40 | -0.26 | -0.53 |
Diluted Net EPS (GAAP) | NA | -0.38 | -0.40 | -0.26 | -0.53 |